Editas Medicine Inc expected to post a loss of 57 cents a share - Earnings Preview

Editas Medicine

27/10/2023 19:29

* Editas Medicine Inc  EDIT.OQ   EDIT.O  is expected to show
a
rise in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 8,042.1% increase in revenue to $3.42 million from $42
thousand a year ago, according to the mean estimate from 13
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Editas Medicine Inc
is
for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Editas
Medicine
Inc is $12​, above​ its last closing price of $6.51. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.76       -0.76      -0.56     Beat    26.6
 Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4
 Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7​
 Sep. 30 2022  -0.83       -0.87      -0.81     Beat    6.8
 ​​Jun.        -0.81       -0.82      -0.78     Beat    5.1
 30 2022                                                
 Mar. 31 2022  -0.78       -0.80      -0.74     Beat    6.9​
 Dec. 31 2021  -0.68       -0.72      -0.61     Beat    15.4
 Sep. 30 2021  -0.83       -0.82      -0.57     Beat    30.2
 This summary was machine generated October 27 at 18:29 GMT.  All
figures in US dollars  unless otherwise stated